Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
about
Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancerPredictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinomaNivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experiencePD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsTumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenibPD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressivenessThe prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosisDifferential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.Tumor-associated antigen CAPERα and microvessel density in hepatocellular carcinoma.Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics.Nivolumab in renal cell carcinoma: latest evidence and clinical potential.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Single versus combination immunotherapy drug treatment in melanoma.Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingRenal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?Sunitinib in kidney cancer: 10 years of experience and development.Immuno-Oncology: The Third Paradigm in Early Drug Development.Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.Advances on immunotherapy in genitourinary and renal cell carcinomaExpression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas.Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinomaUpdated recommendation on molecular-targeted therapy for metastatic renal cell cancer.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaTumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients.Immune checkpoint inhibitors in renal cell carcinoma.The immunocheckpoints in modern oncology: the next 15 years.Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma.
P2860
Q28066532-A850EB82-946F-4145-8A68-D954D337FB8FQ28067482-0F8E10E9-F2DF-4573-8B50-C50D57F216FFQ28068959-198E3387-5063-40F6-958B-4CDB3A273916Q28075712-E6382D68-4AB9-436F-8ADC-9C9D4592CCE7Q33665833-1C349170-BABD-485A-B27F-7FDF1341241AQ33704636-46F51935-5FBC-41DC-B41C-EBD3F12CA8C4Q33842185-621683CD-1EF3-45B9-8853-6437C9CB49A0Q35809165-86BAE3C6-A931-4E04-BA3E-D9C623A9848FQ36132720-E7BD3927-6A53-4BD1-A087-2727B37703C7Q36359469-148989A8-9B8C-40DF-A9EA-56B13A789DC7Q36413093-AE20ABAE-E7FB-4251-BAF1-6B08D9FAD902Q36478715-5FB509B3-7783-45B6-B4D3-25070F832AB4Q36939402-719A9E89-7933-4B8F-8316-57E1C5B933ACQ37086180-69718E07-71E0-4503-9BA0-C87DAD9644BBQ37148917-F2CA9312-4A86-4335-B19F-5A52B503A93BQ37474651-2A4B1CE9-2B58-4E49-81B4-9A3B23230102Q37698611-D17ACC8C-B2F7-4154-9CCF-D7209E42014DQ37705021-974EA2F7-E430-43DA-942F-1F7F926C645AQ38647604-CE68766D-DEEE-4129-9857-474DB82F7F0EQ38661099-159F40C6-E57B-4857-9EBA-52A13E56AED2Q38700735-34AB9C30-B242-433F-A75D-9F652498FA09Q38734141-561541A5-8D5C-42AE-AFD1-E4FB41C2E84CQ38742200-F0F14A48-9797-49C3-9CC5-74E7D7D19290Q38936104-EA7D18AB-FC17-4787-8BDA-29A505D9ADC9Q38968504-DFD1133B-14ED-471C-9688-0CD1DC271C0DQ39012781-A9B9D685-69EF-448C-889B-7BB30C77E49CQ39038214-5F48501D-2AEB-4D43-99A7-8F08B46C7D2CQ39044147-25301104-96FD-4C42-BA7C-7281D6C80E73Q39120161-112ACB3A-7720-481D-AE8D-A44AE037A87DQ39395931-EFF06CC3-5703-4192-BD09-A3017265D3F7Q40498385-3A4F3434-25D2-4867-8F45-59234D4513DAQ41687389-20F57DC0-AA58-4BB4-879E-1DABC9853685Q41695085-FFC7B4B7-6B44-47AB-B221-A645FB9C99D2Q42371619-4A5FB9DF-2E8E-48C1-9B3F-99143B52296DQ42376423-080BBC39-2DC4-4035-B901-71B398815614Q46540302-F1BBAC0E-8198-4B2C-9F89-8985293378E5Q47108251-081BEF5E-5719-4D91-8519-95B472FF1164Q47592718-D7FFA6AE-A377-44DB-88FC-1318D10CAEB3Q48461416-786D195D-8099-4716-8A63-9A48FB0C4D47Q50105512-7CA917CD-4FA0-41D9-98C5-93B1B815FF44
P2860
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@en
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@nl
type
label
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@en
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@nl
prefLabel
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@en
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@nl
P2093
P1476
Correlation of PD-L1 tumor exp ...... a randomized controlled trial.
@en
P2093
André P Fay
Christopher Carpenter
David J Figueroa
Keith Deen
Lini Pandite
Paul de Souza
Peter Benson
Robert Gagnon
Sabina Signoretti
Thomas Powles
P304
P356
10.1158/1078-0432.CCR-14-1993
P407
P577
2014-12-23T00:00:00Z